Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 19/20 | 0.49 |
| ▸ | TNK1 | Q13470 | 11/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 6/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406134 | 0.83 | PARP1 (0.42) | PARP1TNK1TNK2KCNH2PARP2 | |
| SCHEMBL6405680 | 0.83 | PARP1 (0.64) | PARP1TNK1TNK2KCNH2PARP2 | |
| SCHEMBL6555534 | 0.81 | DRD2 (0.54) | PARP1TNK1TNK2KCNH2PARP2 | |
| Hydrochloric Acid SCHEMBL6411449 | 0.80 | DRD2 (0.53) | PARP1TNK1TNK2KCNH2PARP2 | |
| SCHEMBL6407854 | 0.71 | PARP1 (0.51) | PARP1TNK1TNK2KCNH2PARP2 | |
| SCHEMBL11794667 | 0.70 | MAPT (0.46) | — | |
| SCHEMBL6645304 | 0.69 | PIK3CD (0.49) | PARP1TNK1TNK2 | |
| SCHEMBL6556204 | 0.69 | PARP1 (0.53) | PARP1TNK1TNK2KCNH2PARP2 | |
| SCHEMBL25093566 | 0.68 | PARP1 (0.51) | PARP1KCNH2PARP2 | |
| SCHEMBL6406366 | 0.68 | PARP1 (0.62) | PARP1TNK1TNK2KCNH2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171101-A1 | Phenanthridinones as parp inhibitors | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1487800-A1 | PHENANTHRIDINONES AS PARP INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003080581-A1 | PHENANTHRIDINONES AS PARP INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171101-A1 | Phenanthridinones as parp inhibitors | PARP1, PARP11, PARP2 | PARP1 1/4885TNK1 1696/4885TNK2 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.